Webinar: Patient-Derived Tumor Organoids for Personalized Medicine & Targeted Drug Discovery
Presenter: Motoki Takagi, Ph.D., Professor, Medical-industrial Translational Research Center, Fukushima Medical University
Since Dr. Takagi is located in Japan, we will be recording and making his presentation available on-demand on May 30th. Registrants will be able to submit questions during registration as well as after viewing the webinar. Questions that cannot be answered during the webinar will be responded to by email after the event.
Synopsis: Patient-derived tumor organoids (PDOs) are cell aggregates produced by in vitro cell cultures of tumor tissue resected from patients. It is thought that PDOs better represent characteristics of tumor tissues in human body than ordinary cell lines. Therefore, they are considered as a more effective tool for the elucidation of cancer mechanisms and evaluation of anti-cancer agents. During the Fukushima Translational Research project*, PDOs were determined to be more similar to clinical tumor samples than ordinary cell lines in terms of gene expression profiling and thusly were coined as Fukushima PDOs (F-PDOs). This webinar is designed to introduce F-PDOs and present their features as well as the evaluation results of anti-cancer agents using F-PDOs.
Key concepts discussed in this webinar will include:
- Establishment and features of F-PDO
- Difference between F-PDO and other PDOs
- Anti-cancer drug evaluation using F-PDO
- Advantages of F-PDO on PDX mouse development
*The Fukushima Translational Research project (Fukushima Project) was launched as part of the post-Great East Japan Earthquake reconstruction measures supported by the Ministry of Economy, Trade and Industry. The goal of the Fukushima project is to maximize the utilization of rare and trace biological samples by facilitating optimal:
- Conversion into information
- Sample processing and production of pathological models
- Analytical technique development for ultratrace samples